When combined with KRAS activation, loss of ARID1A in the pancreas accelerated the formation of intraductal pancreatic mucinous neoplasms (IPMNs) and pancreatic cancer.21, 22. This evidence concerns the gene ARID1A and familial pancreatic carcinoma.